CHLOROPTIC
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROPTIC is an ophthalmic solution approved in 1968 for eye care indications. The generic name and mechanism of action are not publicly disclosed in available data. It is a small-molecule eye drop formulation administered topically.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the commercial team is likely focused on lifecycle extension or managed decline strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and an LOE-approaching lifecycle, CHLOROPTIC represents a maintenance or legacy product with limited growth opportunities. Career roles would emphasize lifecycle management, competitive positioning, and managed transition rather than launch or expansion activities.
Product ManagerMarket Access
Worked on CHLOROPTIC at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.